GlassScriptPhysician profile
Eric J Lipson
NPI 1023081346
$12,823.76
in general payments reported to CMS, 2019-2025
43 companies · $6,237 in 2025
The $6,237 reported for 2025 was more than what 90% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $349 · 2021: $1,110 · 2022: $1,140 · 2023: $1,142 · 2024: $2,168 · 2025: $6,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,665 · Education: $2,500 · Travel and Lodging: $2,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,665.16 |
| Education | $2,500.00 |
| Travel and Lodging | $2,382.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,675.75 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,644.11 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $1,577.47 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Inspire Medical Systems, INC. | $960.57 | 2023-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $919.36 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Olympus Corporation of The Americas | $727.48 | 2021-2022 | |
| Harmony Biosciences LLC | $253.52 | 2021-2025 | |
| Electromed, INC. | $206.48 | 2021-2025 | Smartvest |
| Insmed, INC. | $149.80 | 2020-2025 | Brinsupri, Arikayce |
| Si-Bone, INC. | $133.85 | 2025 | |
| Mylan Specialty L.P. | $121.43 | 2019-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $119.16 | 2019-2022 | |
| Amgen INC. | $118.23 | 2023-2025 | Tezspire |
| Mallinckrodt Enterprises LLC | $114.28 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $113.08 | 2021-2025 | Dupixent |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $103.49 | 2021-2025 | Ocrevus |
| Pulmonx Corporation | $81.14 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Verona Pharma, INC. | $74.34 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $70.61 | 2019-2024 | |
| United Therapeutics Corporation | $58.19 | 2024 | Tyvaso |
| Medtronic, INC. | $56.56 | 2023-2024 | Illumisite |
| Lundbeck LLC | $52.77 | 2024 | Vyepti |
| Alexion Pharmaceuticals, INC. | $51.08 | 2023-2024 | Ultomiris, Soliris |
| Teva Pharmaceuticals USA, INC. | $49.12 | 2022 | |
| Mallinckrodt Hospital Products INC. | $40.95 | 2023-2024 | Acthar |
| Sk Life Science, INC. | $35.19 | 2024 | |
| Boston Scientific Corporation | $26.80 | 2025 | Vercise |
| Argenx US, INC. | $24.69 | 2025 | Vyvgart Hytrulo |
| Baxter Healthcare | $23.43 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Neurelis, INC. | $21.82 | 2025 | Valtoco |
| Abbvie INC. | $20.40 | 2024 | |
| Merck Sharp & Dohme LLC | $19.98 | 2023 | |
| Grifols USA, LLC | $19.40 | 2019 | |
| Philips North America LLC | $19.27 | 2020 | |
| Genzyme Corporation | $18.70 | 2024 | |
| Tanabe Pharma America, INC. | $18.53 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $18.01 | 2023 | Nuedexta |
| Allergan, INC. | $16.31 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.17 | 2024 | Quviviq |
| Circassia INC. | $15.70 | 2019 | |
| Olympus America INC. | $14.06 | 2021 | |
| Pfizer INC. | $12.62 | 2022 | |
| Inogen, INC. | $9.86 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lipson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.